Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (987)	4/18/1999 1:30:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

Rman: Thanks, good discussion, lots of salient points and interesting questions. I'm very conservative.... I believe that patents should issue when functions are assigned to genes. However, I'll also go with what is allowed and invest on that basis. Gladly. Ethics can come to play later, I want to know what is actually happening as a basis for investment, and your pulse on INCY is invaluable. >> These are pretty meaningless SNPs because they code for the same protein even though the DNA is different. << I strongly disagree. SNPs are the interface of classical, population-based genetics and molecular biology. There's lots left to learn from phenotypes. Thanks again..... really appreciate the effort. The pharma consortium can be regarded from a stand of complexity or from one of simple clarity..... INCY and GENXY are the leaders in providing a product which is in great demand. Rick